Income Statement Vanda Pharmaceuticals Inc.
Equities
VNDA
US9216591084
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.180 USD | +3.17% |
|
-3.89% | -29.93% |
| May. 07 | Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026 | |
| May. 06 | Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 269M | 254M | 193M | 199M | 216M | |||||
Total Revenues | 269M | 254M | 193M | 199M | 216M | |||||
Cost of Goods Sold, Total | 25.63M | 24.28M | 14.8M | 11.31M | 13.04M | |||||
Gross Profit | 243M | 230M | 178M | 187M | 203M | |||||
Selling General & Admin Expenses, Total | 124M | 136M | 113M | 146M | 238M | |||||
R&D Expenses | 75.36M | 85.77M | 76.82M | 74.43M | 109M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 1.48M | 1.52M | 2.09M | 7.27M | 7.01M | |||||
Other Operating Expenses, Total | 201M | 224M | 192M | 228M | 354M | |||||
Operating Income | 42.16M | 6.33M | -13.95M | -40.66M | -151M | |||||
Interest And Investment Income | 199K | 4.97M | - | - | 10.47M | |||||
Net Interest Expenses | 199K | 4.97M | - | - | 10.47M | |||||
Currency Exchange Gains (Loss) | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | - | - | 11.49M | 10.74M | - | |||||
EBT, Excl. Unusual Items | 42.36M | 11.3M | -2.46M | -29.92M | -141M | |||||
Gain (Loss) On Sale Of Investments | - | - | 8.8M | 6.99M | 2.05M | |||||
EBT, Incl. Unusual Items | 42.36M | 11.3M | 6.34M | -22.92M | -139M | |||||
Income Tax Expense | 9.21M | 5.02M | 3.83M | -4.02M | 81.83M | |||||
Earnings From Continuing Operations | 33.15M | 6.28M | 2.51M | -18.9M | -220M | |||||
Net Income to Company | 33.15M | 6.28M | 2.51M | -18.9M | -220M | |||||
Net Income - (IS) | 33.15M | 6.28M | 2.51M | -18.9M | -220M | |||||
Net Income to Common Incl Extra Items | 33.15M | 6.28M | 2.51M | -18.9M | -220M | |||||
Net Income to Common Excl. Extra Items | 33.15M | 6.28M | 2.51M | -18.9M | -220M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.6 | 0.11 | 0.04 | -0.33 | -3.74 | |||||
Basic EPS - Continuing Operations | 0.6 | 0.11 | 0.04 | -0.33 | -3.74 | |||||
Basic Weighted Average Shares Outstanding | 55.55M | 56.46M | 57.38M | 58.15M | 58.93M | |||||
Net EPS - Diluted | 0.58 | 0.11 | 0.04 | -0.33 | -3.74 | |||||
Diluted EPS - Continuing Operations | 0.58 | 0.11 | 0.04 | -0.33 | -3.74 | |||||
Diluted Weighted Average Shares Outstanding | 56.92M | 56.98M | 57.56M | 58.15M | 58.93M | |||||
Normalized Basic EPS | 0.48 | 0.13 | -0.03 | -0.32 | -1.49 | |||||
Normalized Diluted EPS | 0.47 | 0.12 | -0.03 | -0.32 | -1.49 | |||||
Supplemental Items | ||||||||||
EBITDA | 45.01M | 9.06M | -10.94M | -32.53M | -143M | |||||
EBITA | 43.64M | 7.84M | -11.86M | -33.39M | -144M | |||||
EBIT | 42.16M | 6.33M | -13.95M | -40.66M | -151M | |||||
EBITDAR | 47.71M | 11.66M | -8.34M | -29.88M | -140M | |||||
Total Revenues (As Reported) | 269M | 254M | 193M | 199M | 216M | |||||
Effective Tax Rate - (Ratio) | 21.74 | 44.47 | 60.42 | 17.54 | -59.02 | |||||
Current Domestic Taxes | 2.2M | 3.71M | 5.02M | 2.4M | 240K | |||||
Current Foreign Taxes | 267K | 185K | 91K | 58K | 143K | |||||
Total Current Taxes | 2.47M | 3.9M | 5.12M | 2.46M | 383K | |||||
Deferred Domestic Taxes | 6.72M | 1.13M | -1.27M | -6.48M | 81.41M | |||||
Deferred Foreign Taxes | 22K | 3K | -15K | -3K | 38K | |||||
Total Deferred Taxes | 6.74M | 1.13M | -1.28M | -6.48M | 81.44M | |||||
Normalized Net Income | 26.48M | 7.06M | -1.54M | -18.7M | -87.94M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 6.7M | 2.6M | 500K | 1.9M | 28.6M | |||||
Selling and Marketing Expenses | 6.7M | 2.6M | 500K | 1.9M | 28.6M | |||||
Research And Development Expense From Footnotes | 75.36M | 85.77M | 76.82M | 74.43M | 109M | |||||
Net Rental Expense, Total | 2.7M | 2.6M | 2.6M | 2.65M | 2.68M | |||||
Stock-Based Comp., R&D Exp. (Total) | 3.96M | 3.96M | 3.32M | 2.96M | 2.37M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 11.42M | 12.32M | 10.72M | 9.47M | 7.11M | |||||
Total Stock-Based Compensation | 15.37M | 16.28M | 14.04M | 12.43M | 9.47M |
- Stock Market
- Equities
- VNDA Stock
- Financials Vanda Pharmaceuticals Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















